Registro Latinoamericano de Diálisis y Trasplante, Sociedad Latinoamericana de Nefrología e Hipertensión, Montevideo, Uruguay.
Registro Latinoamericano de Diálisis y Trasplante, Sociedad Latinoamericana de Nefrología e Hipertensión, Montevideo, Uruguay; Nephrology Service, Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Rev Invest Clin. 2023;75(6):300-308. doi: 10.24875/RIC.23000224.
Kidney replacement therapy (KRT) initiated in Latin America towards the second half of the 20th century, starting with dialytic therapies and, shortly thereafter, with kidney transplant. By the end of 2021, close to half a million Latin Americans were under KRT, with an overall unadjusted prevalence of 872 per million persons (pmp), yet with significant heterogeneity between nations. By treatment modality, 68% of prevalent patients were treated with hemodialysis (HD), 9% with peritoneal dialysis (PD), and 23% were living with a functioning kidney graft (LFG). In the last decade, HD is the KRT that has had the largest growth, and it also has incorporated newer and better technologies. Nevertheless, Latin America shows heterogeneity between countries, and as a region we are far from achieving full accessibility to all in need of KRT. While there has been growth and improvement in existing renal dialysis registries, and several countries that did not previously have these registries have implemented them, there are still some nations with limited or absent registry implementation. The number of nephrologists in the region is heterogeneous, with only four countries having an appropriate group of specialists. The remaining nations have an important need to expand nephrology training programs. SLANH is a major regional player in addressing these topics and supporting the expansion of appropriate nephrology programs to improve inequalities and patient care. (Rev Invest Clin. 2023;75(6):300-8).
在 20 世纪后半叶,拉丁美洲开始进行肾脏替代疗法(KRT),最初采用透析疗法,随后不久便开始进行肾移植。截至 2021 年底,近 50 万拉丁美洲人接受了 KRT,未经调整的总患病率为每百万人 872 人(pmp),但各国之间存在显著差异。按治疗方式划分,68%的现患患者接受血液透析(HD)治疗,9%接受腹膜透析(PD)治疗,23%的患者有功能的肾脏移植物(LFG)。在过去十年中,HD 是 KRT 中增长最快的治疗方式,并且它还采用了更新、更好的技术。然而,拉丁美洲国家之间存在差异,作为一个地区,我们远未实现所有需要 KRT 的人都能充分获得治疗。虽然现有的肾脏透析登记处有所发展和改善,并且以前没有这些登记处的几个国家已经实施了这些登记处,但仍有一些国家的登记处实施有限或不存在。该地区的肾病学家人数存在差异,只有四个国家拥有适当数量的专科医生。其余国家有扩大肾病学培训计划的重要需求。SLANH 是解决这些问题的主要地区性参与者,并支持扩大适当的肾病学计划,以改善不平等和患者护理。(Rev Invest Clin. 2023;75(6):300-8)。